This listing is restricted to laboratory research-use-only review
For a detailed description of the above mutations in genes encoding for ion channels and transporters, and additional genetic information provided from KO mouse models, see recent reviews, refs
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
Our internal studies have shown a remarkable 64-fold increase in plasma glutathione levels and a 40% increase in whole blood glutathione with WBCILs Liposomal Glutathione
It neutralizes free radicals, which are known for damaging cells and contributing to aging and various chronic health challenges
2019;14:e0215748
